## Summary
[RAB35 AS1](/details-gene/127138862) is a non-coding antisense RNA located on human chromosome 12q24.23. As its name implies, it is transcribed from the strand opposite to the protein-coding gene *RAB35*, a member of the RAS oncogene family involved in vesicle trafficking. Current expression data indicates that [RAB35 AS1](/details-gene/127138862) has a highly restricted expression pattern, with its significance being most pronounced in [retina horizontal cells](/details-cell/CL0000745). This specificity suggests a specialized role in the function or maintenance of this particular neuronal subtype within the retinal circuitry.
## Cellular Roles and Expression Landscape
The expression profile of [RAB35 AS1](/details-gene/127138862) is characterized by its high degree of cellular specificity. **Overall**, the most significant expression is observed in the [retina horizontal cell](/details-cell/CL0000745) (CSI: 3.01), a class of interneurons in the vertebrate retina crucial for mediating lateral inhibition and shaping the receptive fields of photoreceptors and bipolar cells. This strong, cell-type-specific expression suggests that [RAB35 AS1](/details-gene/127138862) is not a broadly expressed regulatory molecule but rather serves a dedicated function within the visual processing network of the outer plexiform layer. Given its antisense nature, it is likely involved in regulating the expression or function of the sense-strand gene, *RAB35*, which itself plays roles in neurite outgrowth and endocytic recycling, processes vital for synaptic maintenance and plasticity in neurons.
## Pathways and Molecular Function
Formal functional annotation for [RAB35 AS1](/details-gene/127138862) is limited. However, its primary molecular function can be inferred from its identity as an antisense non-coding RNA. It is hypothesized to act as a post-transcriptional regulator of *RAB35*. This regulation could occur through several mechanisms, including the formation of an RNA-RNA duplex that either promotes mRNA degradation, inhibits translation, or alters RNA splicing. By controlling the levels of *RAB35*, [RAB35 AS1](/details-gene/127138862) may indirectly influence cellular pathways related to membrane trafficking, such as endosomal recycling and exocytosis, which are fundamental to the synaptic activity and structural integrity of [retina horizontal cells](/details-cell/CL0000745).
## Research Directions
The highly specific expression of [RAB35 AS1](/details-gene/127138862) in a single retinal cell type makes it an intriguing subject for further investigation, particularly concerning retinal health and disease.
Based on the available data, several testable hypotheses can be proposed:
1. [RAB35 AS1](/details-gene/127138862) functions as a negative regulator of *RAB35* expression in [retina horizontal cells](/details-cell/CL0000745), thereby fine-tuning synaptic vesicle turnover and influencing the strength of lateral inhibition in the retina in response to different light conditions.
2. The expression of [RAB35 AS1](/details-gene/127138862) is critical for the terminal differentiation or long-term survival of [retina horizontal cells](/details-cell/CL0000745), and its dysregulation could be implicated in retinal degenerative diseases that affect the outer plexiform layer.
A key experiment to test the first hypothesis would be to use antisense oligonucleotides (ASOs) to specifically knock down [RAB35 AS1](/details-gene/127138862) in human retinal organoids. Following knockdown, changes in *RAB35* mRNA and protein levels could be quantified via qRT-PCR and immunohistochemistry, respectively. Functional consequences could be assessed by examining the morphology of horizontal cell neurites and by using electroretinography (ERG) or calcium imaging on the organoid to measure changes in retinal network activity.
Given its non-coding nature and high cell-type specificity, [RAB35 AS1](/details-gene/127138862) could represent a potential therapeutic target. If its overexpression or underexpression is linked to a specific retinal pathology, ASO-based therapies delivered intravitreally could be developed to either inhibit or stabilize the transcript, respectively. Its specificity to [retina horizontal cells](/details-cell/CL0000745) is a significant advantage, as it may allow for targeted intervention with a reduced risk of off-target effects in other retinal cell types.
Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.